Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project

Cancer

Volumn 120, Issue 16, 2014, Pages 2464-2471

  Carson, Kenneth R ^a   Newsome, Scott D ^b   Kim, Ellen J ^c   Wagner Johnston, Nina D ^a   Von Geldern, Gloria ^b   Moskowitz, Craig H ^d   Moskowitz, Alison J ^d   Rook, Alain H ^c   Jalan, Pankaj ^e   Loren, Alison W ^f   Landsburg, Daniel ^f   Coyne, Thomas ^g   Tsai, Donald ^f   Raisch, Dennis W ^h   Norris, Leann B ⁱ   Bookstaver, P Brandon ⁱ   Sartor, Oliver ^a,j   Bennett, Charles L ^i,k,l  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e ILLINOIS COLLEGE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF NEW MEXICO   (United States)

ⁱ University of South Carolina   (United States)

^j TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF SOUTH CAROLINA   (United States)

^l MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

more..

Author keywords

autoimmune; brentuximab; fungoides; immunocompromised; lymphoma; vedotin

Indexed keywords

ALPHA INTERFERON; BEXAROTENE; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CYTARABINE; DACARBAZINE; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; GAMMA INTERFERON; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; NAVELBINE; PRALATREXATE; PREDNISONE; ROMIDEPSIN; VINBLASTINE; ANTIBODY CONJUGATE; CAC10-VCMMAE;

ADULT; AGED; AMNESIA; APHASIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CEREBROSPINAL FLUID EXAMINATION; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; CONFUSION; CUTANEOUS T CELL LYMPHOMA; DEATH; DRUG WITHDRAWAL; DYSARTHRIA; FEMALE; GAIT DISORDER; HEMIANOPIA; HEMIPARESIS; HUMAN; HUMAN TISSUE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; JC VIRUS; LARGE CELL LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; MYCOSIS FUNGOIDES; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; PHOTOTHERAPY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SALVAGE THERAPY; SPINAL CORD BIOPSY; YOUNG ADULT; CHEMICALLY INDUCED; HODGKIN DISEASE; LYMPHOMA, PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL; MIDDLE AGED;

ADULT; AGED; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LYMPHOMA, PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL; MIDDLE AGED; MYCOSIS FUNGOIDES;

EID: 84905667133     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28712     Document Type: Article

References (29)

1. Cinque P, Casari S, Bertelli D,. Progressive multifocal leukoencephalopathy, HIV, and highly active antiretroviral therapy. N Engl J Med. 1998; 339: 848-849.
2. Sacktor N,. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol. 2002; 8 (suppl 2): 115-121.
3. Brooks BR, Walker DL,. Progressive multifocal leukoencephalopathy. Neurol Clin. 1984; 2: 299-313.
4. Garcia-Suarez J, de Miguel D, Krsnik I, Banas H, Arribas I, Burgaleta C,. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol. 2005; 80: 271-281.
5. Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR,. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int. 2005; 17: 658-665.
6. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009; 10: 816-824.
7. Tan IL, McArthur JC, Clifford DB, Major EO, Nath A,. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011; 77: 1061-1067.
8. Harrison DM, Newsome SD, Skolasky RL, McArthur JC, Nath A,. Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy. J Neuroimmunol. 2011; 238: 81-86.
9. Major EO,. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010; 61: 35-47.
10. Ransohoff RM,. Natalizumab for multiple sclerosis. N Engl J Med. 2007; 356: 2622-2629.
11. Fox RJ, Rudick RA,. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology. 2012; 78: 436-437.
12. US Food and Drug Administration. FDA Public Health Advisory Updated Safety Information about Raptiva (efalizumab). fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm110605. htm. Access date.
13. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009; 113: 4834-4840.
14. National Cancer Institute. FDA Approval for Brentuximab Vedotin. cancer.gov/cancertopics/druginfo/fda-brentuximabvedotin. Accessed on March 17, 2013.
15. Adcetris (Brentuximab Vedotin) Package Insert. accessdata.fda.gov/ drugsatfda-docs/label/2011/125388s000,125399s000lbl.pdf. Accessed on May 14, 2013.
16. Adcetris (Brentuximab Vedotin) Package Insert. accessdata.fda.gov/ drugsatfda-docs/label/2012/125388s0005lbl.pdf. Accessed on May 14, 2013.
17. Bennett CL, Nebeker JR, Yarnold PR, et al. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med. 2007; 167: 1041-1049.
18. Jalan P, Mahajan A, Pandav V, Bekker S, Koirala J,. Brentuximab associated progressive multifocal leukoencephalopathy. Clin Neurol Neurosurg. 2012; 114: 1335-1337.
19. Wagner-Johnston ND, Bartlett NL, Cashen A, Berger JR,. Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma. 2012; 53: 2283-2286.
20. von Geldern G, Pardo CA, Calabresi PA, Newsome SD,. PML-IRIS in a patient treated with brentuximab. Neurology. 2012; 79: 2075-2077.
21. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012; 366: 1870-1880.
22. Molloy ES, Calabrese LH,. Therapy: targeted but not trouble-free: efalizumab and PML. Nat Rev Rheumatol. 2009; 5: 418-419.
23. Zeiser R, Nguyen VH, Hou JZ, et al. Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. Blood. 2007; 109: 2225-2233.
24. van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP,. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med. 2013; 368: 1658-1659.
25. Gerstner ER, Abrey LE, Schiff D, et al. CNS Hodgkin lymphoma. Blood. 2008; 112: 1658-1661.
26. Marzocchetti A, Di Giambenedetto S, Cingolani A, Ammassari A, Cauda R, De Luca A,. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol. 2005; 43: 4175-4177.
27. Ryschkewitsch CF, Jensen PN, Major EO,. Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variants. J Clin Virol. 2013; 57: 243-248.
28. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012; 30: 2183-2189.
29. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012; 30: 2190-2196.